508
Participants
Start Date
December 31, 2006
Primary Completion Date
January 31, 2008
agomelatine
placebo
Novartis Investigative Site, New York
Novartis Investigative Site, Brooklyn
Novartis Investigative Site, Rockville
Novartis Investigative Site, Salisbury
Novartis Investigative Site, Midlothian
Novartis Investigative Site, North Charleston
Novartis Investigative Site, Marietta
Novartis Investigative Site, Atlanta
Novartis Investigative Site, Atlanta
Novartis Investigative Site, Jacksonville
Novartis Investigative Site, Maitland
Novartis Investigative Site, Port Charlotte
Novartis Investigative Site, Bradenton
Novartis Investigative Site, Nashville
Novartis Investigative Site, Beachwood
Novartis Investigative Site, Dayton
Novartis Investigative Site, Rochester Hills
Novartis Investigative Site, Farmington Hills
Novartis Investigative Site, City of Saint Peters
Novartis Investigative Site, Overland Park
Novartis Investigative Site, Little Rock
Novartis Investigative Site, Tulsa
Novartis Investigative Site, Dallas
Novartis Investigative Site, Houston
Novartis Investigative Site, Austin
Novartis Investigative Site, Salt Lake City
Novartis Investigative Site, Scottsdale
Novartis Investigative Site, Albuquerque
Novartis Investigative Site, Cerritos
Novartis Investigative Site, San Diego
Novartis Investigative Site, El Centro
Novartis Investigative Site, Temecula
Novartis Investigative Site, Irvine
Novartis Investigative Site, Garden Grove
Novartis Investigative Site, Lafayette
Novartis Investigative Site, Eugene
Novartis Investigative Site, Bothell
Novartis Investigative Site, Cromwell
Novartis Investigative Site, Hamden
Novartis Investigative Site, Pittsfield
Novartis Investigative Site, Princeton
Novartis Investigative Site, Bennington
Novartis Investigative Site, Bayamón
Novartis Investigative Site, Rio Piedras
Lead Sponsor
Novartis
INDUSTRY